Small-molecule GLP-1RA litigation over the coming decade will likely generate more numerous, more independently contested patent challenges than peptide GLP-1RA litigation has
Approach them with caution
Since GLP-1s reduce your appetite, you need to make every bite count
This increases companies exposure to fluctuating raw material costs and volatile supplies
Join us in person in Washington DC on Wednesday July 26, 2026 for Axios Live Examining Risk and Regulation in the GLP-1 Landscape Speakers include The Honorable Nikki Budzinski (IL-13), Scott Kahan, M.D., M.P.H., F.T.O.S., Shabbir Imber Safdar, CFE, The Honorable Rudy Yakym (IN-02) The study found that 91.8% of the platforms issued a prescription
What are the long-term benefits versus risks of using Tirzepatide